Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
0(0%)
Results Posted
47%(7 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_2
1
6%
Ph phase_3
6
38%
Ph phase_1
9
56%

Phase Distribution

9

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
9(56.3%)
Phase 2Efficacy & side effects
1(6.3%)
Phase 3Large-scale testing
6(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(15)
Terminated(1)

Detailed Status

Completed15
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
93.8%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (56.3%)
Phase 21 (6.3%)
Phase 36 (37.5%)

Trials by Status

terminated16%
completed1594%

Recent Activity

0 active trials
Showing 5 of 16
terminatedphase_3

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048
completedphase_3

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

NCT03188185
completedphase_3

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NCT02218008
completedphase_3

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

NCT02085135
completedphase_3

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

NCT02158546
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT03610048Phase 3

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

Terminated
NCT03188185Phase 3

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Completed
NCT02218008Phase 3

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

Completed
NCT02085135Phase 3

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

Completed
NCT02158546Phase 3

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study

Completed
NCT01500200Phase 2

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

Completed
NCT02141399Phase 3

A Long-Term Safety Study of ALKS 5461

Completed
NCT02508506Phase 1

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

Completed
NCT02452801Phase 1

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Completed
NCT02479308Phase 1

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

Completed
NCT02521857Phase 1

A Water Consumption Study of ALKS 5461 in Healthy Volunteers

Completed
NCT02413281Phase 1

A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users

Completed
NCT02545439Phase 1

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

Completed
NCT02272764Phase 1

A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers

Completed
NCT02068105Phase 1

A Study of ALKS 5461 in Healthy Volunteers

Completed
NCT01381107Phase 1

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16